IL-32c is a multifunctional cytokine involved in various inflammatory and auto-immune diseases in which neutrophils can affect the evolution of these diseases. To persist at inflammatory sites, neutrophils require inhibition of their rapid and constitutive apoptosis, an inhibitory effect that phlogogenic cytokines support. To date, the effects of IL-32c on neutrophils remain unknown. We demonstrate that IL-32c delays, in a dose-dependent manner, the spontaneous apoptosis of human blood neutrophils by activating mainly p38 MAPK through rapid p38 phosphorylation. PI3-K and ERK1/2 MAPK are also involved, but to a lesser extent. Most of cytokines that induce retardation of neutrophil apoptosis activate the expression of MCL-1 at both mRNA and protein levels. IL-32c added to human blood neutrophils in vitro is associated with sustained levels of MCL-1 protein. This effect in neutrophils corresponds to a decrease of MCL-1 protein degradation without any effect on MCL-1 mRNA levels. The sustained levels of MCL-1 induced by IL-32c are only abrogated by the p38b MAPK inhibitor SB202190. Additionally, IL-32c induces a reduction in caspase 3 activity in neutrophils. In conclusion, IL-32c affects human blood neutrophils in vitro by increasing their survival, suggesting that this cytokine could have profound effects on the deleterious functions of neutrophils in several diseases.
Introduction
Neutrophils are terminally differentiated cells that, in homeostatic conditions, constitutively undergo apoptosis in vivo and in vitro [1] . Circulating neutrophils can be considered as resting cells that remain in the blood a few hours only [2] . This short circulatory lifespan can greatly increase during infection and inflammation in response to secretion of cytokines and growth factors. These situations delay apoptosis of neutrophils, the lifespan of which can then be extended to a few days. Prolonged survival of neutrophils allows them to efficiently perform their functions of defence. Neutrophil apoptosis is also delayed in vitro by various cytokines including granulocyte-macrophage colonystimulating factor (GM-CSF), G-CSF, interleukin-1 (IL-1), IL-4 or IL-6 [3, 4, 5, 6] . Retardation of neutrophil apoptosis by cytokines, inflammatory mediators or microorganisms could, however, lead to persistent inflammation and tissue damage induced by secretion of cytotoxic molecules such as reactive oxidants and proteases [7, 8, 9] .
Since neutrophils are constitutively programmed for rapid cellular apoptosis, the earliest modification of neutrophils involved in host reactions to extracellular stimuli corresponds to the delay of their spontaneous apoptosis. However, the large spectrum of neutrophil functions that can lead to inflammation requires tight control of neutrophil survival and apoptosis [10, 11] . This complex control uses extrinsic and intrinsic pathways [11] . Among the extrinsic pathways are anti-apoptotic factors such as cytokines/ growth factors and pro-apoptotic factors such as FasL/TRAIL. On the other hand, caspases and Bcl-2 family member proteins are the main intrinsic pathways [10] . However, most of these pathways are differentially regulated by phosphorylation/dephosphorylation states in which phosphatidylinositol 3-kinase (PI3-K) and mitogen-activated protein kinase (MAPK) cascades are mostly involved [12, 13, 14, 15] .
Neutrophils express most of the pro-apoptotic caspases that are subdivided into initiator and effector caspases (respectively caspases 8, 9, 10, and 3, 6, 7) [10, 16] . In addition, caspase 3, which is highly expressed in neutrophils, represents a critical enzymatic step to induce neutrophil apoptosis by cleaving cellular proteins, nuclear DNA and NFk-B [17, 18, 19] . Besides caspases, members of the Bcl-2 protein family also tightly regulate neutrophil apoptosis [20] . Regarding this protein family, human neutrophils express the pro-apoptotic proteins Bax, Bid, Bak, and Bad that remain stable with long half-lives, and the anti-apoptotic proteins MCL-1 (myeloid cell leukemia 1), A1 and Bcl-X that are unstable and short-lived [21] . However, human neutrophils do not express Bcl-2 or Bcl-X at the protein level [21, 22] . To date, MCL-1 is undoubtedly the most studied survival protein of neutrophils present in different in vitro and in vivo stimulatory conditions, since MCL-1 is a regulatory protein influenced by many pro-and anti-apoptotic signals [22, 23, 24] . More specifically, cytokineactivated survival of neutrophils has been shown to critically depend on cellular levels of MCL-1 [4, 22] . This major antiapoptotic factor for neutrophils is very rapidly transcribed [25, 26] . However, cytokine-induced increases in MCL-1 seem to be regulated more at the protein level than at the mRNA level [24] . For instance, GM-CSF up-regulates MCL-1 mainly by stabilizing its expression at the protein level [27] . In addition, mature MCL-1 has a very short (,5 hr) half-life, and MCL-1 amounts have been inversely correlated to neutrophil apoptosis [28, 29] . The protein MCL-1 is characterized by several phosphorylation sites that allow tight up-and down-regulation of neutrophil survival [30] . Thus, experiments with highly purified human neutrophils suggested that at early timepoints MCL-1 decreases before caspase 3 activation, and at later timepoints reduction of MCL-1 amounts depends on caspase activity [31] .
Interleukin-32 (IL-32), originally reported as natural killer (NK) transcript 4, is a newly described multifunctional cytokine mainly produced by activated cells like T lymphocytes, NK cells, monocytes and epithelial cells [32, 33, 34] . IL-32 presents proinflammatory properties and influences innate as well as adaptive immune responses [35, 36, 37] . There are six splice variants of IL-32 (IL-32a, IL-32b, IL-32c, IL-32d, IL-32e, and IL-32f), among which the c isoform has the longest sequence associated to a protein with the most efficient biological activity [38, 39] . Overexpression of IL-32c has been associated with cell death in T lymphocytes and HeLa cells [39] . In addition, IL-32c inhibited tumor development by interfering, at least in part, with the expression of anti-apoptotic genes [40] . This interleukin induces a variety of proinflammatory cytokines such as TNF-a, IL-1b, IL-6 or IL-8 [33, 41] . Moreover, IL-32 has been shown to be associated with various inflammatory and auto-immune pathologies such as rheumatoid arthritis, inflammatory bowel diseases and certain cancers [42, 43, 44, 45, 46, 47] . Also, neutrophils are recognized as major players in immune diseases and cancers [48, 49, 50, 51] . Thus, IL-32 appears to be a critical proinflammatory cytokine that impacts immune responses, but whether or not neutrophils can be affected by IL-32 remains unknown.
In the present investigation, we aimed to determine whether IL32c affects survival of human neutrophils. We demonstrated that IL-32c significantly delays the spontaneous apoptosis of neutrophils. Studies with pharmacological inhibitors suggested the involvement of p38 MAPK and PI3-K in IL-32c anti-apoptotic signals resulting in MCL-1 stabilization and caspase-3 inhibition. These data indicate that IL-32c, by increasing the lifespan of mature neutrophils, could be responsible for persistent inflammation and tissue damage associated with chronic inflammatory diseases.
Materials and Methods

Reagents and antibodies
The incubation medium RPMI 1640, FBS, penicillin/streptomycin and Ficoll were obtained from Wisent (St-Bruno, QC, Canada). Dextran was from Sigma-Aldrich Corp. (St. Louis, MO, USA). Recombinant human IL-32c, ApoStat detection kit and TACS annexin V-FITC apoptosis detection kit were purchased from R&D Systems (Minneapolis, MN, USA). The inhibitors of PI3K/Akt (LY294002) and MEK-1 (U0126) were obtained from Cayman Chemical (Ann Arbor, Michigan, USA). The JNK inhibitor (SP600125) was from Calbiochem (San Diego, CA, USA), p38 MAPK inhibitor (SB202190) was obtained from Invivogen (San Diego, CA, USA), and MAPK inhibitor negative control (SB202474) was from Life Technologies (Carlsbad, CA, USA). The fluorescein active caspase-3 staining kit was purchased from BioVision (Milpitas, CA, USA) and the caspase-3 (active form) apoptosis kit was from BD Biosciences (San Jose, CA, USA). Antibodies were from different sources as follows: anti-human CD66b-FITC and control isotype were from BioLegend (San Diego, CA, USA), anti-human MCL-1 and anti-human PCNA (PC-10) were from Santa Cruz Biotechnologies (Dallas, TX, USA), anti-human phopho-p38 and anti-human p38 MAPK were from Cell Signaling Technologies (Danvers, MA, USA), and antihuman b-actin was from Sigma-Aldrich Corp. (St. Louis, MO, USA).
Isolation and incubation of neutrophils
The institutional review board of the Université Laval (Québec, QC, Canada) approved this study and healthy adult volunteers signed a consent form. Peripheral blood neutrophils were prepared in sterile conditions at room temperature, as previously described [52] . Briefly, human venous blood collected on citrate phosphate dextrose adenine anticoagulant solution was centrifuged (2506g, 10 min) to remove the platelet-rich plasma. After dextran sedimentation of the erythrocytes, neutrophils were purified by centrifugation over a Ficoll-Paque cushion (4506g, 20 min). Neutrophils were collected at the bottom and contaminating erythrocytes were eliminated by hypotonic lysis. Neutrophils were counted and suspended in the appropriate medium: RPMI 1640+ 10% FBS for long-term incubation ($2 hrs) or HBSS for shortterm incubation (#1 hr). In order to exclude potential monocyte contamination, cell purity was routinely assessed by fluorescence activated cell sorting (FACS) using an anti-CD66b antibody [53] and was .99.5%. Neutrophils (10 7 cells/ml) were incubated (37uC, 5% CO 2 ) with IL-32c, pharmacological inhibitors or their vehicle for the indicated times.
Annexin V-FITC binding evaluation
Non-apoptotic and non-necrotic neutrophils were referred to as viable cells. Neutrophil apoptosis was evaluated with the TACS annexin V-FITC apoptosis detection kit, as suggested by the manufacturer. Neutrophils were simultaneously stained with FITC-labeled annexin V and propidium iodide (PI) to discriminate between early and late apoptosis and necrosis. Briefly, 5610 5 neutrophils were incubated 15 min on ice in 100 mL of binding buffer containing Annexin V-FITC and PI, in the dark. Ten thousand cells were then counted and analyzed by FACS using the FACScalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
Measurement of pan-caspase activity
Cells undergoing apoptosis were irreversibly labeled with a cell permeable, FITC-conjugated pan-caspase inhibitor (ApoStat assay FITC-VD-FMK). Cells were then analyzed by flow cytometry for the presence of bound reagent. The test was performed as specified by the manufacturer. Briefly, 10 6 neutrophils were incubated with or without IL-32c for 48 hrs, Apostat-FITC was added directly to the cells for the last 30 min of incubation (37uC, 5% CO 2 ), in the dark. Cells were then washed in PBS and analyzed by FACS. Fluorescence intensity was proportional to cells undergoing apoptosis.
Active caspase-3 measurement
The fluorescein active caspase-3 staining kit was used to detect activated caspase-3 in living cells. The caspase-3 inhibitor, DEVD-FMK conjugated to FITC (DEVD-FMK-FITC), is used as a marker and irreversibly binds to activated caspase-3 in apoptotic cells. The test was performed as specified by the manufacturer. Briefly, 10 6 neutrophils were incubated with or without IL-32c for 48 hrs, DEVD-FMK-FITC was added directly to the cells for the last 30 min of culture (37uC, 5% CO 2 ), in the dark. Cells were then washed twice in wash buffer and analyzed by FACS. Fluorescence intensity was proportional to cells with activated caspase-3.
The caspase-3 (active form) apoptosis kit was also used to detect apoptotic cells. The test was performed as specified by the manufacturer. Briefly, 10 6 neutrophils were incubated with or without IL-32c for 48 hrs. After fixation and permeabilisation steps, cells were incubated 30 min in the dark with an antibody that specifically recognizes the active form of caspase-3. Cells were then washed and analyzed by FACS. Fluorescence intensity was proportional to cells undergoing apoptosis.
RNA isolation and RT-PCR
Total RNA of neutrophils was isolated using trizol (Life Technologies, Carlsbad, CA, USA). Briefly, 10 7 cells stimulated or not with IL-32c (500 ng/ml) were homogenized in 1 ml Trizol. Total RNA was then extracted, according to the manufacturer's protocol. Reverse-transcription and PCR were then performed. 
Immunoblot analysis
Neutrophils (5610 6 cells) were treated with IL-32c in the presence or absence of kinase inhibitors, and cells were harvested, washed with PBS and then directly lysed in Laemmli buffer. Samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes (Bio-Rad Laboratories, Mississauga, ON, Canada). Equal protein loading and transfer efficiency were visualized by b-actin detection. Membranes were saturated for 40 min at room temperature in Tris-buffered saline (TBS: 25 mM Tris-HCl pH 7.6, 0.2 M NaCl) with 0.5% Tween 20, containing 5% (w/v) dried milk and subsequently incubated overnight at 4uC with anti-MCL-1, antiphospho-p38, anti-p38 or 1 hr at room temperature with the antib-actin antibody, followed by incubation with secondary antibodies. Bound antibodies were revealed with Western Lightning Plus ECL, as specified by the manufacturer's protocol (PerkinElmer, Waltham, MA, USA).
Densitometric analysis
Immunoblots and cDNA amplifications were analyzed using Image Lab software and band intensity was quantified by densitometry. Results are presented as mean values of arbitrary densitometric units normalized to the expression of b-actin.
Statistical analysis
Results are expressed as mean 6 SEM. Statistical analyses were performed using GraphPad Instat 3.0 (GraphPad Software Inc., San Diego, CA, USA). Two groups were analyzed using paired t tests. For three groups or more, statistical analyses were performed by using the one-way ANOVA Bonferroni multiple comparison test or the repeated measures ANOVA. Significance was set at P, 0.05.
Results and Discussion
IL-32c delays spontaneous apoptosis of neutrophils
Several cytokines/growth factors, such as TNF-a or GM-CSF associated with the inflammatory process delay neutrophil apoptosis [22, 54, 55] . Knowing that IL-32 contributes to inflammation in rheumatoid arthritis, inflammatory bowel disease and cancer [43, 46, 47] , chronic diseases in which neutrophils are implicated, we investigated the effect of IL-32c, the longest and the most active isoform, on neutrophil apoptosis. Evaluation of apoptosis was performed using two techniques that assess different markers of apoptosis: 1/the binding of annexin V to phosphatidylserine on the outer surface of neutrophils, a well-recognized method for flow cytometric detection of early apoptotic cells [56] , and 2/the binding of a labeled pan-caspase inhibitor to the active caspase enzymes. In addition to the evaluation of annexin V, membrane-permeable late-apoptotic and necrotic cells were evaluated by PI, a fluorescent dye which stains DNA by intercalating between bases and which is excluded from viable cells. Apoptosis was studied using healthy human blood neutrophils incubated in the presence or absence of graded concentrations of IL-32c (Figure 1) .
Viable neutrophils are non-apoptotic cells that are not stained by annexin V or PI. After 24 hrs of incubation with vehicle, the normal neutrophil population can be arranged into four categories characterized by different percentages that vary with experimental conditions: 23.963.5% non-apoptotic (annexin V and PI negative), 53.062.1% early apoptotic (annexin V positive and PI negative), 20.464.3% late apoptotic (annexin V positive and PI positive) and 2.761.0% necrotic (annexin V negative and PI positive) cells ( Figure 1A) . In contrast to vehicle, IL-32c increased the percentage of non-apoptotic neutrophils while reducing percentages of early and late apoptotic cells without significant modification of necrotic cells, in a dose-dependent manner. Remarkably, after 24 hrs of incubation IL-32c maintained at least twice as many neutrophils in a non-apoptotic state compared to vehicle: percentages of annexin V negative/PI negative cells decreased from 54.968.7% in the presence of 300 ng/ml IL-32c and from 67.666.9% with 1000 ng/ml IL-32c to 23.963.5% in control conditions ( Figure 1B ). This effect was more pronounced at 48 hrs ( Figure 1C) , since IL-32c maintained neutrophils in a non-apoptotic state at least 4 times more efficiently than did vehicle: percentages of annexin V negative/PI negative cells decreased from 28.565.9% (incubation with 300 ng/ml IL-32c) and from 42.567.9% (with 1000 ng/ml IL-32c) to 7.261.2% (incubation with vehicle). A representative FACS analysis of neutrophils incubated with vehicle or IL-32c is shown in Figure 1A . In addition, IL-32c reduced the levels of active pancaspase in a dose-dependent manner, which indicated an inhibitory effect of IL-32c on neutrophil apoptosis ( Figure 1D ). In fact, kinetics and amplitude of the inhibitory effect of IL-32c on neutrophil apoptosis were similar to those of other cytokines which delay neutrophil apoptosis, such as GM-CSF, IL-8 or TNF-a [22, 54, 55, 57, 58, 59] . It is also useful to stress that, in addition to pancreatic cancer cells in which IL-32 reduces cellular apoptosis [44] , neutrophils are the second cell type reported to show an increase in survival in the presence of IL-32.
IL-32c-delayed apoptosis depends on p38 MAP Kinase and PI3-Kinase Spontaneous (or constitutive) neutrophil apoptosis, as well as neutrophil apoptosis retarded by extracellular stimuli produced during the inflammatory process, are tightly regulated for maintaining cell homeostasis [11, 20] . Mechanisms that regulate the effects of anti-apoptotic factors involve various kinase cascades like PI3-kinases/Akt, MAP kinases, PKCd, JNK and STAT [11, 58, 60] . Therefore, to investigate kinase pathways that could be involved in the regulation of IL-32c-delayed apoptosis of neutrophils, pharmacological inhibitors at optimal concentrations were used to study the role of PI3-K, p38 MAPK, ERK and JNK activation in this anti-apoptotic effect.
LY294002, an inhibitor of class I PI3-K [61] , inhibited the antiapoptotic effect of IL-32c by 51% (Table 1) . U0126, a selective MEK inhibitor targeting ERK1/2 MAPK [62, 63] , inhibited the anti-apoptotic effect of IL-32c by 29%. Preincubation with SP600125, an inhibitor of JNK [64] , did not affect the antiapoptotic effect of IL-32c. Inhibition of p38b MAPK by pretreating neutrophils with SB202190 [65] reduced IL-32c effects on neutrophil survival by 68%. It is useful to point out that the major function of the b isoform of p38 MAPK relates to survival [66] , and that SB202190 abrogated p38 MAPK without inhibiting ERK and JNK activity [67, 68] . As a control for SB202190 effectiveness, pretreating neutrophils with SB202474, the inactive analog of SB202190, did not influence IL-32c effects on neutrophil survival (dat not shown).
These pharmacological results suggested that p38b MAPK could be a major kinase pathway in IL-32c-delayed apoptosis of neutrophils. Thus, the next step was to verify whether IL-32c could phosphorylate p38 leading to MAPK activation. As expected, IL-32c stimulated the phosphorylation of p38 MAPK (Figure 2) . Kinetics of this p38 phosphorylation took the shape of a bell curve with the onset at 10 min followed by a peak at 20-30 min and with the end at 60 min.
Interestingly, IL-32 was initially shown to increase phospho-p38 MAPK expression within 5 min followed by a decrease from 15 to 30 min and a second increase at 45 min that thereafter diminished slowly [33] . Regarding our results, the p38 MAPK pattern of human neutrophil response to IL-32c with one peak only is similar to that seen in RAW cells, a mouse leukaemic monocytemacrophage cell line used in the first report. Although the initial findings were obtained with IL-32a in murine immortalized myeloid cells, the phosphorylation of p38 MAPK stimulated by IL-32 appears to be a major activation pathway of this new cytokine. This rapid increase in phospho-p38 MAPK is also a hallmark of cell activation by other cytokines known to reduce apoptosis, such as GM-CSF and TNF-a [59] . In addition, the absence of involvement of the JNK MAPK pathway in IL-32c-stimulated neutrophils could be related to the well-documented interplay between the p38 MAPK and JNK pathways in which p38 MAPK negatively regulates JNK activity [69] .
IL-32c induces sustained amounts of neutrophil MCL-1 protein
The pro-and anti-apoptotic proteins of the Bcl-2 family are currently recognized as major regulators of neutrophil death and survival. For example, the stable pro-apoptotic protein Bax in its serine phosphorylated form heterodimerizes with the labile antiapoptotic protein MCL-1, a condition that maintains Bax in the cytoplasm and lengthens the survival of neutrophils by reducing Bax translocation to the mitochondria [21, 70] . Moreover, MCL-1 is reported as the predominant anti-apoptotic Bcl-2 family member in neutrophils [71, 72] . Cytokines that induce a delay of neutrophil apoptosis most often depend on synthesis of new proteins by neutrophils, in particular of MCL-1 [22, 23, 29, 73] . Table 1 . Effects of signaling inhibitors on IL-32c delayed apoptosis. Therefore, we investigated the effects of IL-32c on MCL-1 expression by neutrophils at the mRNA and protein levels.
Neutrophils in the presence of IL-32c did not modify their expression of MCL-1 mRNA when compared to neutrophils incubated with vehicle for 2 hrs (Figure 3 ) or up to 20 hrs (data not shown). However, the addition of IL-32c to neutrophils was associated with a sustained level of MCL-1 protein in comparison to the major decrease in MCL-1 protein levels after 20 hrs of incubation of neutrophils with vehicle ( Figure 4 ). MCL-1 protein levels in neutrophils incubated with IL-32c for 20 hrs were twice as high as those of neutrophils incubated with vehicle, and this effect persisted at 30 hrs of incubation ( Figure 4B ). On the other hand, Bcl-2 expression was under the detection limit in neutrophils incubated with vehicle or with IL-32c (data not shown), as previously reported with other anti-apoptotic factors [21] .
As PI3-K, ERK1/2 and p38 MAPK inhibitors modulated IL32c-delayed apoptosis of neutrophils (Table 1) , their effects on MCL-1 expression were then investigated. All three inhibitors studied affected the basal levels of MCL-1 expression in neutrophils incubated with vehicle. However, pretreating neutrophils with the p38b MAPK inhibitor SB202190 was the sole condition that abrogated the increase of MCL-1 expression induced by IL-32c ( Figure 5 ). In contrast, the effects of LY294002 and U0126 were slight and non-significant. Therefore, IL-32c delays constitutive neutrophil apoptosis by modulating MCL-1 protein amounts without affecting MCL-1 mRNA. It is likely that IL-32c induced an increase in steady state levels of MCL-1 by preventing its degradation. In addition, the modulation of MCL-1 amounts in neutrophils is mainly controlled by the p38 MAPK pathway, and both PI3-kinases and ERK1/2 MAPK pathways could be implicated in the regulation of anti-apoptotic proteins other than MCL-1.
To date, no report has mentioned an effect of IL-32 on MCL-1 at the protein level. The only condition in which IL-32 has been shown to affect MCL-1 was in pancreatic cancer cells that constitutively expressed IL-32a, where knockdown of IL-32a was shown to decrease MCL-1 mRNA with no data at the protein level [44] . Interestingly, the effect of IL-32c on neutrophil MCL-1 protein without any effect on MCL-1 mRNA differs from that of other anti-apoptotic factors such as GM-CSF, TNF-a or LTB 4 which were shown to upregulate the transcription of MCL-1 in neutrophils [14, 22, 24, 27, 73] . However, several reports suggest that neutrophil survival stimulated by cytokines is not mainly regulated at the transcriptional level [24] . In addition, the absence of IL-32c effects on MCL-1 transcription in neutrophils eliminates certain activation pathways involved in survival such as NF-kB.
Although IL-32 has been shown to activate the NF-kB pathway, the presence of NF-kB binding sites described in the promoter region of MCL-1 has not been demonstrated in neutrophils [30, 74, 75, 76] . Therefore, the anti-apoptotic effect of IL-32c on neutrophils implicates a post-transcriptional modulation in which the p38 MAPK cascade appears to be the main regulator of MCL-1 protein levels. Although the role of p38 MAPK in neutrophils apoptosis seems contradictory, with pro-and anti-apoptotic effects depending on the stimulus used [12, 20, 60, 77, 78] , one of the mechanisms associated with these opposing effects corresponds to the activation intensity of MAPK, and a strong p38 MAPK activity leads to apoptosis whereas a low p38 MAPK activity favors cell survival [69, 79] . Thus, our results indicate that in human neutrophils the main pathway involved in the increase in survival induced by IL-32c depends on a rapid phosphorylation of p38 MAPK, which remains low enough to lead to post-transcriptional modulation of MCL-1. Additionally, since inhibition of PI3-K and ERK1/2 pathways did not significantly alter MCL-1 protein upregulation but modulated the effect of IL-32c on neutrophil apoptosis, PI3K and ERK1/2 activation could be associated with the regulation of other survival genes of Bcl-2 family members. It is useful to note that, for instance, GM-CSF can decrease the rate of MCL-1 turnover by inhibiting the proteasome, an effect regulated by PI3K and ERK signals [27] . Thus, it remains possible that IL- 32c could inhibit the proteasome leading to MCL-1 stability. However, the downregulation of neutrophil apoptosis by IL-32c appears different from that of other cytokines such as GM-CSF or TNF-a in which PI3K and ERK pathways are strongly involved [57, 58, 80] . On the other hand, neutrophil apoptosis reduced by G-CSF has been associated with the increase in a new factor named proliferating cell nuclear antigen (PCNA) [81] . Unlike G-CSF, IL-32c did not induce any change in PCNA as evaluated by immunoblot analysis of human neutrophils incubated in vitro (data not shown; n = 3).
IL-32c decreases caspase-3 activity in neutrophils
Caspase 3 has been shown to be a major effector caspase in neutrophil death [17] . Interestingly, MCL-1 has recently been shown to downregulate caspase activation before being reduced by caspases themselves [31] . Thus, the increase in MCL-1 protein without mRNA change observed in neutrophils incubated with IL32c could be related to a reduction in caspase activity. To investigate whether IL-32c is able to delay neutrophil apoptosis through a reduction in caspase activity, we compared the levels of active caspase-3 in neutrophils incubated with IL-32c or with its vehicle for 48 hrs ( Figure 6 ). The addition of IL-32c to neutrophils reduced by 30% the number of caspase-3-positive cells from 42.963.7% with vehicle to 30.763.1% with IL-32c, as assessed by a caspase-3 inhibitor which binds to the active enzyme ( Figure 6A ). Similarly, an antibody specific to the active form of caspase-3 showed a significant reduction in this pro-apoptotic enzyme in neutrophils incubated with IL-32c ( Figure 6B ).
It is noteworthy that in human neutrophils p38 MAPK directly phosphorylates caspases 3 and 8 leading to decrease neutrophil apoptosis [12] . Since the major signaling pathway activated during IL-32c-induced reduction of apoptosis and IL-32c-stimulated increase in MCL-1 in human neutrophils is p38 MAPK (Figures 2,  5, 6 ), it is very likely that the anti-apoptotic effect of IL-32c on neutrophils implicates a reduction of caspase 3 activity through its phosphorylation by IL-32c-activated p38MAPK.
Conclusion
To perform their functions during the inflammatory process associated with auto-immune diseases and cancers [48, 49, 50, 51] , neutrophils have to persist in tissues and their survival becomes a key event of their functional condition. The pro-inflammatory cytokine IL-32c shows a strong inhibitory effect on neutrophil apoptosis mediated through a decrease of the protein MCL-1 degradation. The present data support the fact that this sustained MCL-1 level induced by IL-32c in neutrophils may be directly related to the effect of p38 MAPK that reduces caspase 3 activity, and thereby increases neutrophil survival. In addition, IL-32c through PI3-K and ERK1/2 pathways could modulate antiapoptotic proteins other than MCL-1. An important finding of the present study relates to a new mechanism through which IL-32c could induce and perpetuate inflammation. Our data are the first demonstration that human neutrophils can respond to IL-32c and increase their survival. Regarding the unique role of neutrophils in inflammation, the effects of IL-32c on this cell type could be associated with tissue damage seen in various pathologies. 
